Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial

DOI: 10.2217/fmb.14.78
Future Microbiology, 2014, 9, 1013-23.

#	Paper	IF	Citations
33	Dermatological Drugs, Topical Agents, and Cosmetics. *Side Effects of Drugs Annual*, **2015**, 175-184	0.2	1
32	Advances in the medical management of skin and soft tissue infections. *BMJ, The*, **2016**, 355, i6004	5.9	10
31	In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan. *Journal of Infection and Chemotherapy*, **2016**, 22, 720-3	2.2	8
30	Childhood skin and soft tissue infections: new discoveries and guidelines regarding the management of bacterial soft tissue infections, molluscum contagiosum, and warts. *Current Opinion in Pediatrics*, **2016**, 28, 250-7	3.2	14
29	American Academy of Dermatology Annual Meeting : Orlando, FL, USA, 3-7 March 2017. *American Journal of Clinical Dermatology*, **2017**, 18, 299-301	7.1	
28	Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates. *Future Microbiology*, **2018**, 13, 3-19	2.9	13
27	Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus. *Future Microbiology*, **2018**, 13, 21-30	2.9	6
26	A review of the antibacterial activity of ozenoxacin. *Future Microbiology*, **2018**, 13, 1-2	2.9	6
25	Ozenoxacin: A Novel Topical Quinolone for Impetigo. *Annals of Pharmacotherapy*, **2018**, 52, 1233-1237	2.9	6
24	Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs. *Future Microbiology*, **2018**, 13, 31-40	2.9	7
23	Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. *JAMA Dermatology*, **2018**, 154, 806-813	5.1	27
22	Transferable Mechanisms of Quinolone Resistance from 1998 Onward. *Clinical Microbiology Reviews*, **2019**, 32,	34	28
21	Ozenoxacin: a review of preclinical and clinical efficacy. *Expert Review of Anti-Infective Therapy*, **2019**, 17, 159-168	5.5	21
20	Microbiological profile of ozenoxacin. *Future Microbiology*, **2019**, 14, 773-787	2.9	4
19	Common Community-acquired Bacterial Skin and Soft-tissue Infections in Children: an Intersociety Consensus on Impetigo, Abscess, and Cellulitis Treatment. *Clinical Therapeutics*, **2019**, 41, 532-551.e17	3.5	20
18	Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo. *International Journal of Womens Dermatology*, **2020**, 6, 109-115	2	3
17	Impetigo Animal Models: A Review of Their Feasibility and Clinical Utility for Therapeutic Appraisal of Investigational Drug Candidates. *Antibiotics*, **2020**, 9,	4.9	1

16	New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics. *Pharmaceuticals*, **2020**, 13,	5.2	5
15	The Use of Ozenoxacin in Pediatric Patients: Clinical Evidence, Efficacy and Safety. *Frontiers in Pharmacology*, **2020**, 11, 559708	5.6	2
14	Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents. *Dermatology*, **2020**, 236, 199-207	4.4	12
13	Antibacterial lead compounds and their targets for drug development. **2020**, 275-292		4
12	Topical Antibacterial Agents. **2021**, 465-479.e9		0
11	Ozenoxacin: A novel topical antibiotic. *Indian Journal of Dermatology, Venereology and Leprology*, **2021**, 87, 131-134	0.8	1
10	Emerging Treatment Strategies for Impetigo in Endemic and Nonendemic Settings: A Systematic Review. *Clinical Therapeutics*, **2021**, 43, 986-1006	3.5	0
9	New FDA approved antibacterial drugs: 2015-2017. *Discoveries*, **2018**, 6, e81	3.7	23
8	Krentenbaard/impetigo. **2017**, 317-321		
7	Natural history of non-bullous impetigo: a systematic review of time to resolution or improvement without antibiotic treatment. *British Journal of General Practice*, **2021**, 71, e237-e242	1.6	
6	Treatment of Impetigo with Antiseptics-Replacing Antibiotics (TIARA) trial: a single blind randomised controlled trial in school health clinics within socioeconomically disadvantaged communities in New Zealand.. *Trials*, **2022**, 23, 108	2.8	
5	Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain. 9, 133-137		1
4	Ozenoxacin: A novel topical quinolone. **2022**, 8, 211-216		0
3	Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS). 10,		0
2	A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects. **2023**, 28, 1762		0
1	Retrospective Analysis of the Real-World Use of Topical Antimicrobials in the Paediatric Population with Impetigo in Italy: Focus on the Role of Ozenoxacin 1% Cream. **2023**, 10, 547		0